Verona Pharma plc
NASDAQ: VRNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David S. Zaccardelli
- Employees
- 209
- Headquarters
- London, United Kingdom
- IPO year
- 2017
- Market cap
- $72.7B
- Website
- https://www.veronapharma.com
Loading VRNA…
Loading profile data…Frequently asked questions about VRNA
What does Verona Pharma plc (VRNA) do?
Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously blo...
Where does VRNA trade?
Verona Pharma plc (VRNA) trades on the NASDAQ Global Market.
What sector is VRNA in?
Verona Pharma plc (VRNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Verona Pharma plc?
David S. Zaccardelli is the chief executive officer of Verona Pharma plc (VRNA).
Where is Verona Pharma plc headquartered?
Verona Pharma plc is headquartered in United Kingdom.
Does VRNA pay a dividend?
Verona Pharma plc (VRNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VRNA go public?
Verona Pharma plc (VRNA) completed its initial public offering in 2017.
Is VRNA an ADR?
Yes — VRNA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Verona Pharma plc reporting and dividends follow the underlying issuer.